Phase 2 Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have acute myeloid leukemia (AML) that has come back or has not responded to previous treatment, based on specific 2022 medical guidelines
- People aged 18 to 70 years
- People whose overall health means doctors consider them able to tolerate intensive (strong) chemotherapy
- People who are willing and able to provide written consent to participate
Who may not be able to join:
- People who have a specific type of leukemia called acute promyelocytic leukemia (APL), which involves particular genetic changes in the blood cells
- People whose leukemia developed as a progression of a different blood cancer called chronic myeloid leukemia (CML)
- People whose health means doctors consider them unable to tolerate intensive chemotherapy
- People whose condition requires immediate treatment and cannot wait for a specific laboratory test (called PCY) to produce results
- People whose blood sample did not meet the required quality standards for the PCY laboratory test
- People with serious medical, psychiatric, psychological, family, or practical circumstances that, in the lead doctor's judgment, could interfere with the trial or make participation difficult
- People who are legally unable to make their own decisions or who do not have the capacity to give informed consent
- People who have taken part in another clinical trial involving an experimental drug within the 30 days before joining, or who are currently in another such trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Alexandre Theocharides, MD PhD, University of Zurich
Phone: +41 44 633 71 49
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Complete response (CR) rate at day 28
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.